ORIGINAL RESEARCH

Pharmacology

doi: 10.25005/2074-0581-2026-28-1-88-99
QUANTITATIVE ASSESSMENT OF ANTIBIOTIC CONSUMPTION FOR RESPIRATORY DISEASES: A NATIONAL DDD ANALYSIS IN KYRGYZSTAN

E.B. BARBIEVA1, E.B. MURZABAEVA2, I.Z. ISMAILOV1

1Institute of Chemistry and Phytotechnology, National Academy of Science of Kyrgyz Republic, Bishkek, Republic of Kyrgyzstan
2Faculty of Medicine, Ala-Too International University, Bishkek, Republic of Kyrgyzstan

Objective: This study aims to conduct a quantitative assessment of antibiotic consumption for infectious and inflammatory respiratory tract diseases in the Kyrgyz Republic over three years (2021-2023).

Methods: A retrospective analysis of antibiotic consumption in the Kyrgyz Republic (2021-2023) was conducted using the WHO-recommended Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) methodology. The following indicators were assessed: total number of Defined Daily Doses (DDD), DDD per 1,000 inhabitants per day (DID), and packages per inhabitant per year (PIY).

Results: Total antibiotic consumption increased from 1.228 million DDD in 2021 to 1.962 million in 2023. The DID rose from 499 to 797, and the PIY increased from 34 to 46. Penicillins (J01C) were the most frequently used, followed by macrolides (J01F) and fluoroquinolones (J01M). Among individual drugs, amoxicillin was the most common. A reduction in the variety of international nonproprietary names (INNs) was observed, decreasing from 24 to 18 over the study period.

Conclusion: Antimicrobial consumption for respiratory diseases in the Kyrgyz Republic increased significantly between 2021 and 2023. The prevalence of broad-spectrum antibiotics and the decline in therapeutic diversity underscore the urgent need for national antimicrobial stewardship programs and policy measures to mitigate the emergence of AMR.

Keywords: Antibacterial drugs, antimicrobial resistance, DDD analysis, antibiotic consumption.

Download file:


References
  1. Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of antibiotics and antibiotic resistance, and their impacts on drug development: A narrative review. Pharma- ceuticals. 2023;16(11):1615. https://doi.org/10.3390/ph16111615
  2. Volkow ND, Blanco C. Substance use disorders: A comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention. World Psychiatry. 2023;22(2):203-29. https://doi.org/10.1002/ wps.21192
  3. Levin R, Villanueva CM, Beene D, Cradock AL, Donat-Vargas C, Lewis J, et al. US drinking water quality: Exposure risk profiles for seven legacy and emerging contaminants. J Expo Sci Environ Epidemiol. 2024;34(1):3-22. https://doi. org/10.1038/s41370-023-00597-z
  4. Ahmed SK, Hussein S, Qurbani K, Ibrahim RH, Fareeq A, Mahmood KA, et al. Antimicrobial resistance: Impacts, challenges, and future prospects. Journal of Medicine, Surgery, and Public Health. 2024;2:100081. https://doi.org/10.1016/j. glmedi.2024.100081
  5. Mendelson M, Lewnard JA, Sharland M, Cook A, Pouwels KB, Alimi Y, et al. Ensuring progress on sustainable access to effective antibiotics at the 2024 UN General Assembly: A target-based approach. Lancet. 2024;403(10443):2551-64. https://doi.org/10.1016/S0140-6736(24)01019-5
  6. World Health Organization, United Nations Environment Programme, World Organisation for Animal Health. Guidance to facilitate monitoring and evaluation for antimicrobial resistance national action plans. Geneva: WHO; 2023.
  7. Zhazykhbayeva D, Bayesheva D, Kosherova Z, Semenova Y. Antimicrobial resistance surveillance in post-Soviet countries: A systematic review. Antibiotics. 2024;13(12):1129. https://doi.org/10.3390/antibiotics13121129
  8. Struelens MJ, Ludden C, Werner G, Sintchenko V, Jokelainen P, Ip M. Real- time genomic surveillance for enhanced control of infectious diseases and antimicrobial resistance. Front Sci. 2024;2:1298248 https://doi.org/10.3389/ fsci.2024.1298248
  9. World Health Organization. WHO Country Office in Ukraine, 2020-2021 report. Copenhagen: WHO Regional Office for Europe; 2022.
  10. Amaha ND, Weldemariam DG, Berhe YH. Antibiotic consumption study in two hospitals in Asmara from 2014 to 2018 using WHO’s defined daily dose (DDD) methodology. PLoS One. 2020;15(7):e0233275. https://doi.org/10.1371/journal. pone.0233275
  11. Duarte DJ, Zillien C, Kox M, Oldenkamp R, van der Zaan B, Roex E, et al. Characterization of urban sources of antibiotics and antibiotic-resistance genes in a Dutch sewer catchment. Sci Total Environ. 2023;905:167439. https://doi. org/10.1016/j.scitotenv.2023.167439
  12. Van der Meer J, Mamouris P, Nassiri V, Vaes B, van den Akker M. Use of antibiotics and colorectal cancer risk: A primary care nested case-control study in Belgium. BMJ Open. 2021;11(12):e053511. https://doi.org/10.1136/ bmjopen-2021-053511
  13. Nguyen-Thi HY, Bui TV, Tran-Thi HN, Minh Le AD, Gia Nguyen BD, Tran-Thi HN, et al. Evaluation of the impact before and after the application of an antimicrobial stewardship program at Dong Thap General Hospital, Vietnam, from 2017 to 2021. Infect Prev Pract. 2023;5(4):100311. https://doi.org/10.1016/j. infpip.2023.100311
  14. Wei L, Wang T, Luo M, Zhang S, Lu M, Zhou X, et al. A "toxic window" study on the hippocampal development of mice offspring exposed to azithromycin at different doses, courses, and time during pregnancy. Chem Biol Interact. 2024;387:110814. https://doi.org/10.1016/j.cbi.2023.110814
  15. Battini V, Mari A, Gringeri M, Casini F, Bergamaschi F, Mosini G, et al. Antibiotic-induced neutropenia in pediatric patients: New insights from pharmacoepidemiological analyses and a systematic review. Front Pharmacol. 2022;13:877932. https://doi.org/10.3389/fphar.2022.877932
  16. Deshwal PR, Tiwari P. Investigating the variability among indicators for quantifying antimicrobial use in the intensive care units: Analysis of real-world evidence. Indian J Crit Care Med. 2024;28(7):662. https://doi.org/10.5005/jp- journals-10071-24859

Authors' information:


Barbieva Elnura Bekbolotovna,
Post-Graduate Student of Institute of Chemistry and Phytotechnology, National Academy of Science of Kyrgyz Republic
ORCID ID: 0000-0003-2516-4231
E-mail: barbievaeb@mail.ru

Murzabaeva Elvira Bolotbekovna,
Candidate of Pharmaceutical Sciences, Associate Professor of the Faculty of Medicine, Ala-Too International University
ORCID ID: 0000-0002-5258-9879
E-mail: elusya_kg@mail.ru

Ismailov Isabek Zailidinovich,
Doctor of Pharmaceutical Sciences, Professor, Institute of Chemistry and Phytotechnology, National Academy of Science of Kyrgyz Republic
ORCID ID: 0000-0003-4980-8986
E-mail: ism-isa@mail.ru

Information about support in the form of grants, equipment, medications

The author did not receive financial support from manufacturers of medicines and medical equipment

Conflicts of interest: No conflict

Address for correspondence:


Murzabaeva Elvira Bolotbekovna
Candidate of Pharmaceutical Sciences, Associate Professor, Faculty of Medi- cine, Ala-Too International University

720048, Republic of Kyrgyzstan, Bishkek, Ankara str., 1/8

Tel.: +996 (772) 667896

E-mail: elusya_kg@mail.ru


This work is licensed under a Creative Commons Attribution 4.0 International License.

Materials on the topic: